HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort.

Abstract
Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e., decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a case-control study nested within European Prospective Investigation into Cancer and Nutrition. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.23-0.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.67-3.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development.
AuthorsVerena A Grote, Sabine Rohrmann, Laure Dossus, Alexandra Nieters, Jytte Halkjaer, Anne Tjønneland, Kim Overvad, Jakob Stegger, Nathalie Chabbert-Buffet, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Birgit Teucher, Susen Becker, Jukka Montonen, Heiner Boeing, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Domenico Palli, Sabina Sieri, Rosario Tumino, Paolo Vineis, Amalia Mattiello, Marcial Argüelles, Eric J Duell, Esther Molina-Montes, Nerea Larrañaga, María-Dolores Chirlaque, Aurelio Barricarte Gurrea, Suzanne M Jeurnink, Petra Hm Peeters, Weimin Ye, Malin Sund, Björn Lindkvist, Dorthe Johansen, Kay-Tee Khaw, Nick Wareham, Francesca L Crowe, Isabelle Romieu, Sabina Rinaldi, Mazda Jenab, Dora Romaguera, Dominique S Michaud, Elio Riboli, H Bas Bueno-de-Mesquita, Rudolf Kaaks
JournalInternational journal of cancer (Int J Cancer) Vol. 130 Issue 10 Pg. 2428-37 (May 15 2012) ISSN: 1097-0215 [Electronic] United States
PMID21681743 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 UICC.
Chemical References
  • Adiponectin
Topics
  • Adiponectin (blood)
  • Adult
  • Aged
  • Aged, 80 and over
  • Body Mass Index
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 (epidemiology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms (blood)
  • Risk
  • Smoking

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: